Earnings
Home›Earnings›Previews›Alcon and RxSight plan co-development of light-adjusta…
Alcon and RxSight plan co-development of light-adjustable cataract lenses
The non-exclusive collaboration pairs RxSight’s UV light technology with Alcon’s lens commercialization and comes alongside Alcon’s second India training center with Aravind.
Alcon Inc. and RxSight, Inc. entered a non-exclusive strategic collaboration on July 6 to co-develop post-operatively adjustable pseudophakic intraocular lenses, aligning RxSight’s light-adjustable approach with Alcon’s global surgical and commercial capabilities. The companies said RxSight’s technology lets surgeons fine-tune patients’ vision using UV light after surgery.
The partnership is intended to validate RxSight’s platform while expanding Alcon’s premium lens offerings, according to Yahoo Finance. At the same time, Alcon said it strengthened its international presence by opening its second training center in partnership with the Aravind Eye Care System in India on July 24, expanding access to phacoemulsification training and advanced eye care technology.
In financial context, Yahoo Finance highlighted that Alcon’s latest First Quarter 2026 results showed net sales of $2.7 billion, up 10% year-over-year, with surgical sales of $1.5 billion and Vision Care sales of $1.2 billion. The company reported core diluted earnings per share of $0.85, up 16%, and core operating margin of 21.2%, while free cash flow was $279 million, supporting a new $1.5 billion share repurchase authorization.
Yahoo Finance also contrasted RxSight’s quarter, noting revenue of $30.9 million, down 18.5% year-over-year, and attributing the decline to lower sales amid capital spending slowdowns. The article ends mid-sentence after describing RxSight’s revenue drivers, with additional details not included in the provided text.